Up-regulation and clinical relevance of novel helicase homologue DHX32 in colorectal cancer

Huang, Chunling; Liang, Xianming; Huang, Rongfu; Zhang, Zhongying

doi:10.1186/1756-9966-28-11

Cited by 16 publications

(24 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…DEAD box family members are involved in cellular processes regulating RNA secondary structures (Cordin et al, 2006). In many cases, DEAD box proteins exhibit other functions in addition to their ATP hydrolysis and RNA unwinding activities (Jankowsky and Fairman, 2007). Many studies show that DEAD box proteins are implicated in cellular proliferation and/or neoplastic transformation, implying that these molecules play a role in human cancer development (Abdelhaleem, 2004a).…”

Section: Discussionmentioning

confidence: 99%

“…Many DEAD box RNA helicases are overexpressed in tumor cell lines and tumor tissues (Abdelhaleem, 2004b;Fuller-Pace, 2013). DDX5 (Causevic et al, 2001), DDX6 (Nakagawa et al, 1999;Hashimoto et al, 2001), DDX17 (Shin et al, 2007) and DHX32 (Huang et al, 2009) have all been shown to be upregulated in CRC cells. These reports show that DEAD box RNA helicases can promote cancer cell proliferation and contribute to cancer progression and transformation.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Lentiviral DDX46 knockdown inhibits growth and induces apoptosis in human colorectal cancer cells

Huang

et al. 2015

Gene

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Lentiviral DDX46 knockdown inhibits growth and induces apoptosis in human colorectal cancer cells

Huang

et al. 2015

Gene

View full text Add to dashboard Cite

“…DEAH-box polypeptide 32 (DHX32) is a novel RNA helicase containing a unique helicase domain structure and has been observed to be dysregulated in certain types of tumor (6,7). In addition, a number of other RNA helicases have been demonstrated to be dysregulated in various types of cancer, although their exact role in carcinogenesis remains to be completely elucidated (8,9).…”

Section: Introductionmentioning

confidence: 99%

“…In addition, the amino acid sequence of human DHX32 is highly homologous to that of its murine counterpart, with 84% identity and 90% similarity, indicating that it is an evolutionally conserved and functionally important gene (15). A previous study demonstrated that DHX32 is overexpressed in colorectal cancer (CRC) tissue samples compared with adjacent wild-type tissue (7). In addition, DHX32 expression is significantly associated with clinicopathological features of CRC, which suggests that DHX32 may be used as a prognostic biomarker in patients with CRC (7).…”

Section: Introductionmentioning

confidence: 99%

DHX32 expression is an indicator of poor breast cancer prognosis

et al. 2016

View full text Add to dashboard Cite

Abstract. Emerging evidence suggests that DEAH-box polypeptide 32 (DHX32) serves an important role in the progression and metastasis of cancer. However, the role of DHX32 in breast cancer remains to be completely elucidated. The aim of the present study was to evaluate the expression and clinical significance of DHX32 in breast cancer. The reverse transcription-quantitative polymerase chain reaction was performed to analyze DHX32 messenger (m)RNA expression, and western blotting and immunohistochemistry were performed to examine DHX32 protein expression in breast cancer and adjacent non-cancerous tissues. The association in breast cancer between DHX32 expression, clinicopathological features and prognosis was analyzed using 193 breast cancer tissue samples. The results of the present study demonstrated that breast cancer tissues exhibited increased DHX32 mRNA and protein expression compared with adjacent non-cancerous tissues (P<0.001). In addition, DHX32 expression was significantly associated with breast cancer clinical stage (P=0.006), histological grade (P=0.029), lymph node metastasis (P<0.001) and expression of the proliferation marker Ki-67 (P=0.004). Kaplan-Meier estimator analysis indicated that increased DHX32 expression is associated with poor prognosis in patients with breast cancer. Furthermore, the Cox proportional hazards model indicated that DHX32 expression is an independent prognostic factor for decreased overall survival and disease-free survival in patients with breast cancer. In conclusion, the results of the present study suggest that DHX32 overexpression is an unfavorable prognostic biomarker in breast cancer and a potential therapeutic target of future breast cancer treatments.

show abstract

“…Quantitative real-time RT-PCR was performed using gene-specific primers as described in our previous study (Huang et al, 2009). The expression of target transcripts was normalized to the β-actin internal control, and relative changes of gene expression were determined using the 2 − ΔΔCt method.…”

Section: Methodsmentioning

confidence: 99%

DHX32 Promotes Angiogenesis in Colorectal Cancer Through Augmenting β-catenin Signaling to Induce Expression of VEGFA

Lin

Fang

et al. 2017

EBioMedicine

View full text Add to dashboard Cite

We previously reported that overexpression of DHX32 contributes to the growth and metastasis of colorectal cancer (CRC). However, the underlying mechanism is not largely characterized. Herein, we reported that DHX32 in CRC cells upregulated expression of vascular endothelial growth factor A (VEGFA) at the transcription level through interacting with and stabilizing β-catenin. This promoted the recruitment of host endothelial cells to the tumor, and therefore, formation of microvessel in the tumor. Xenograft model revealed that depletion of DHX32 in CRC cells significantly reduced the microvessel density in the grafts and suppressed the growth of grafts. Furthermore, the expression level of DHX32 was positively associated with microvessel density in human CRC and poor outcome of CRC patients. Therefore, the report demonstrates that DHX32 is a pro-angiogenic factor, that inhibition of DHX32-β-catenin pathway can provide a strategy for CRC treatment, and that the expression level of DHX32 has the potential to serve as a biomarker for CRC diagnosis and prognosis.

show abstract

Up-regulation and clinical relevance of novel helicase homologue DHX32 in colorectal cancer

Abstract: Background: This study aimed to find novel biomarkers for colorectal cancer.

Cited by 16 publications

References 28 publications

Lentiviral DDX46 knockdown inhibits growth and induces apoptosis in human colorectal cancer cells

Lentiviral DDX46 knockdown inhibits growth and induces apoptosis in human colorectal cancer cells

DHX32 expression is an indicator of poor breast cancer prognosis

DHX32 Promotes Angiogenesis in Colorectal Cancer Through Augmenting β-catenin Signaling to Induce Expression of VEGFA

Contact Info

Product

Resources

About